Relapsed Acute Lymphoblastic Leukemia All clinical trials

Explore recruiting relapsed acute lymphoblastic leukemia all clinical trials.

Recruiting relapsed acute lymphoblastic leukemia all studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Acute Lymphoblastic Leukemia All trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020

Netherlands, Czechia, Italy, Spain, Denmark, Austria +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease Committee of the International BFM Study Group – IntReALL HR 2010

Czechia, Spain, Belgium, Netherlands, France, Germany +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Relapsed Acute Lymphoblastic Leukemia All trials by city

Relapsed Acute Lymphoblastic Leukemia All clinical trials

Recruiting relapsed acute lymphoblastic leukemia all studies right now

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

Orphan Indications for CD19 Redirected Autologous T Cells

Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Also recruiting in Europe

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020

International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease Committee of the International BFM Study Group – IntReALL HR 2010

Relapsed Acute Lymphoblastic Leukemia All trials by city

Other conditions